How effective is Canafenib/Encofenib?

Encorafenib is an oral kinase inhibitor that may be used in combination with other drugs to treat certain types of cancer. It is approved for the treatment of adult patients with melanoma skin cancer, non-small cell lung cancer, and colorectal cancer with confirmed BRAF V600E or V600K mutations that cannot be treated with surgery or have spread to other parts of the body (metastasized) can be used with drugs such as Binimetinib (bimetinib) and Cetuximab (cetuximab).

1. Melanoma

In a study covering 577 patients with BRAF V600 mutated melanoma, the results showed that the treatment regimen of canafenib combined with binimetinib significantly prolonged the survival of the patients without worsening of the disease. Patients treated with the combination lived an average of nearly 15 months, compared with 9.5 months for those treated with canafenib alone and just 7 months for those treated with vemurafenib.

2. Colorectal cancer(CRC)

In a study involving 665 previously treated patients with BRAF V600E mutated colorectal cancer that had spread to other parts of the body, treatment with canafenib and cetuximab improved response rates and prolonged patients' survival compared with treatment with cetuximab and other cancer drugs. Approximately 20% of patients who received canafenib plus cetuximab responded to treatment, compared with approximately 2% of patients who did not receive canafenib. Patients who took canafenib and cetuximab survived for an average of 9.3 months, compared with 5.9 months for those taking the other drugs.

3. Non-small cell lung cancer

The benefit of combining canafenib with binimetinib was evaluated in a major study involving 98 patients with advanced NSCLC with a BRAF V600E mutation, including those who had not previously received treatment for NSCLC and those who had received treatment. The main measure of effectiveness is the percentage of patients who respond to treatment, with no signs of cancer or a decrease in the extent of their cancer after treatment. About 75% of previously untreated patients responded to canafenib given binimetinib, and they lived an average of 40 months without their cancer getting worse. About 46 percent of previously treated patients responded to the combination, and they lived an average of about 17 months without their cancer getting worse.

In summary, the application of canafenib/encofenib in the treatment of various cancers has shown good efficacy, especially when used in combination, it can significantly improve the survival rate and quality of life of patients.